Nutra Pharma Shifts to In-House Manufacturing, Eyes Orphan Drug Path

TL;DR

**Nutra Pharma is a high-risk bet on niche homeopathic pain relief and early-stage biopharma, with in-house manufacturing a potential game-changer if they can overcome funding and regulatory hurdles.**

AI Summary

Nutra Pharma Corp., a biopharmaceutical company, reported a market value of voting and non-voting common equity held by non-affiliates at $6,762,239 as of its most recently completed second quarter. The company, incorporated in California on February 1, 2000, focuses on drug discovery and development for autoimmune disorders, viral diseases, and pain. Key product launches include Cobroxin (discontinued), Nyloxin (October 2009), Nyloxin Extra Strength (May 2010), Pet Pain-Away (December 2014), Equine Pain-Away (October 2019), and Luxury Feet (March 2021). In March 2022, Nutra Pharma brought all manufacturing in-house, aiming for reduced product costs, higher margins, and faster product upgrades. They also secured their first contract manufacturing agreement with Avini Health, a related party, in March 2022. The company holds Orphan Designation from the US-FDA for Pediatric Multiple Sclerosis treatment, potentially reducing clinical trial costs and accelerating drug approval. A significant risk factor is the FDA warning letter received on March 11, 2019, regarding Nyloxin product claims, which the company addressed by April 10, 2019, making all committed changes to marketing materials.

Why It Matters

Nutra Pharma's strategic shift to in-house manufacturing in March 2022 could significantly impact its cost structure and product development agility, potentially boosting margins for investors. For employees, this move suggests a more integrated and potentially stable operational environment. Customers could benefit from faster product upgrades and new homeopathic pain relief options. In a competitive pain management market, where the global chronic pain intervention market is projected to exceed $117 billion by 2029, Nutra Pharma's focus on non-opioid, non-NSAID alternatives like Nyloxin, derived from Asian cobra venom, positions it uniquely against pharmaceutical giants. The FDA Orphan Designation for Pediatric Multiple Sclerosis also offers a potential fast-track to market for a critical drug candidate, RPI-78M.

Risk Assessment

Risk Level: high — The company faces high risk due to limited funding for clinical studies and marketing, as explicitly stated: "To date, our marketing efforts have been limited due to lack of funding" and "We cannot provide any timeline for these studies until adequate financing is available." Additionally, the removal of Nyloxin from the Federal Supply Schedule in February 2018 without adequate explanation and the prior FDA warning letter in March 2019 highlight significant regulatory and market access challenges.

Analyst Insight

Investors should approach Nutra Pharma with extreme caution, recognizing its speculative nature. Monitor for concrete evidence of increased sales from in-house manufacturing, successful re-listing on the Federal Supply Schedule, and securing adequate financing for clinical trials, as these are critical milestones for de-risking the investment.

Key Numbers

• $6,762,239 — Aggregate market value of common equity held by non-affiliates (As of the most recently completed second quarter)
• 7,099,727,214 — Shares of common stock issued and outstanding (As of November 24, 2025)
• 12,000,000 — Shares of Series B preferred stock issued and outstanding (As of November 24, 2025)
• 21% — Percentage of U.S. population living with chronic pain (51.6 million adults, according to US Pain Foundation)
• $78.79 billion — Global market for chronic pain intervention in 2024 (Expected to exceed $117 billion by 2029)
• 400% — Increase in pain reliever prescriptions in the military (2001-2009) (From 2001 to 2009, reaching 3.8 million prescriptions in 2009)
• 7,600 — Estimated deaths from NSAID use in America annually (With 78,000 hospitalizations)
• 30 mcg/mL — Nyloxin Topical Gel venom dilution (Primary difference in strength for Nyloxin products)
• 60 mcg/mL — Nyloxin Extra Strength Topical Gel venom dilution (Twice the strength of standard Nyloxin Topical Gel)
• 4 times — Duration of pain-reducing effects of RPI-78 compared to morphine (As shown in a study published in Toxicon)

Key Players & Entities

• NUTRA PHARMA CORP. (company) — Registrant and biopharmaceutical company
• ReceptoPharm, Inc. (company) — Wholly owned subsidiary of Nutra Pharma
• Designer Diagnostics Inc. (company) — Wholly owned subsidiary of Nutra Pharma
• Avini Health (company) — Related party and first contract manufacturing client
• US-FDA (regulator) — Granted Orphan Designation and issued warning letter
• The Business Research Company (company) — Source for market data on chronic pain intervention
• US Pain Foundation (company) — Source for statistics on chronic pain prevalence
• Lumaxa Distributors (company) — Initial distributor for Pet Pain-Away
• DEG Productions (company) — Licensee for marketing and distribution of Pet Pain-Away globally
• The Nature's Clinic (company) — Engaged for Canadian regulatory approval of Nyloxin

FAQ

Risk Factors

• FDA Warning Letter [high — regulatory]: The company received an FDA warning letter on March 11, 2019, concerning Nyloxin product claims. Nutra Pharma addressed this by April 10, 2019, by making all committed changes to marketing materials. Failure to comply with FDA regulations can lead to product recalls, fines, and reputational damage.
• Manufacturing and Supply Chain [medium — operational]: Bringing manufacturing in-house in March 2022 aimed to reduce costs and improve margins. However, this also introduces operational risks related to production efficiency, quality control, and potential supply chain disruptions if internal processes are not robust.
• Dependence on Future Funding [high — financial]: As a biopharmaceutical company focused on drug development, Nutra Pharma likely requires significant ongoing capital for research, clinical trials, and regulatory approvals. A lack of sufficient funding could impede development timelines and operational continuity.
• Competition in Pain Management [medium — market]: The chronic pain market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs. Nutra Pharma faces competition from existing treatments and new entrants, requiring significant differentiation and efficacy to gain market share.
• Orphan Drug Designation Risks [medium — regulatory]: While Orphan Designation for Pediatric Multiple Sclerosis treatment can reduce clinical trial costs and accelerate approval, it does not guarantee FDA approval. The company must still meet rigorous efficacy and safety standards.
• Related Party Transactions [low — financial]: The contract manufacturing agreement with Avini Health, a related party, raises potential concerns about fair market value and transparency. Such arrangements require careful scrutiny to ensure they are conducted at arm's length.

Industry Context

Nutra Pharma operates in the highly competitive biopharmaceutical and pain management sectors. The global market for chronic pain intervention is substantial, projected to exceed $117 billion by 2029, driven by an increasing prevalence of chronic pain conditions. The industry faces significant regulatory hurdles and requires substantial R&D investment, with a constant push for novel, effective, and safer therapeutic alternatives to existing treatments like NSAIDs.

Regulatory Implications

The company's operations are heavily influenced by FDA regulations. The prior warning letter regarding Nyloxin product claims underscores the critical need for strict adherence to marketing and labeling guidelines. Obtaining Orphan Designation for a pediatric MS treatment offers potential regulatory advantages but does not guarantee market approval, requiring continued compliance with rigorous FDA standards.

What Investors Should Do

1. Monitor FDA communications and regulatory filings closely.
2. Evaluate the progress and success of in-house manufacturing.
3. Assess the competitive landscape and differentiation of Nyloxin.
4. Scrutinize related-party transactions, particularly the Avini Health agreement.

Key Dates

• 2019-03-11: FDA Warning Letter Issued — Indicated potential non-compliance with marketing claims for Nyloxin, requiring corrective actions and posing a regulatory risk.
• 2019-04-10: Company Addressed FDA Warning Letter — Demonstrated a proactive response to regulatory concerns by implementing necessary changes to marketing materials.
• 2022-03-01: In-house Manufacturing Initiated — Strategic shift to control production costs and margins, but introduces operational execution risks.
• 2022-03-01: Contract Manufacturing Agreement with Avini Health — Secured manufacturing capacity, but involves a related party, requiring careful oversight.

Glossary

Orphan Designation

A designation granted by the FDA to drugs intended to treat rare diseases or conditions affecting fewer than 200,000 people in the U.S. It offers incentives like tax credits and market exclusivity. (Nutra Pharma holds this for a pediatric Multiple Sclerosis treatment, potentially reducing development costs and accelerating FDA approval.)

NSAID

Nonsteroidal Anti-Inflammatory Drug, a class of pain relievers that reduce inflammation and pain. Examples include ibuprofen and naproxen. (The filing notes significant deaths and hospitalizations associated with NSAID use, highlighting a market need for safer alternatives.)

Venom Dilution

Indicates the concentration of active venom components in a topical formulation. A higher dilution (e.g., 60 mcg/mL vs. 30 mcg/mL) means a stronger concentration. (Used to differentiate the strengths of Nutra Pharma's Nyloxin products (Nyloxin vs. Nyloxin Extra Strength).)

Year-Over-Year Comparison

Information comparing key metrics to the previous year, such as revenue growth, margin changes, and the emergence or resolution of risks, is not available in the provided text. The filing details the company's business, risk factors, and market context but does not offer comparative financial performance data from a prior period.

Key Financial Figures

• $0.001 — ction 12(g) of the Act: Common stock, $0.001 par value (Title of Class) Indicate
• $635 billion — daily activities. This costs as much as $635 billion yearly in direct healthcare costs, lost
• $78.79 billion — t for chronic pain intervention reached $78.79 billion in 2024. This is expected to exceed $11
• $117 billion — ion in 2024. This is expected to exceed $117 billion by 2029. This includes prescription and

Filing Documents

• form10-k.htm (10-K) — 2006KB
• ex31-1.htm (EX-31.1) — 20KB
• ex32-1.htm (EX-32.1) — 7KB
• form10-k_001.jpg (GRAPHIC) — 5KB
• audit_002.jpg (GRAPHIC) — 3KB
• 0001493152-25-024800.txt ( ) — 12532KB
• nphc-20231231.xsd (EX-101.SCH) — 75KB
• nphc-20231231_cal.xml (EX-101.CAL) — 79KB
• nphc-20231231_def.xml (EX-101.DEF) — 381KB
• nphc-20231231_lab.xml (EX-101.LAB) — 618KB
• nphc-20231231_pre.xml (EX-101.PRE) — 539KB
• form10-k_htm.xml (XML) — 1767KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 21 Item 1B. Unresolved Staff Comments 26 Item 2.

Properties

Properties 26 Item 3.

Legal Proceedings

Legal Proceedings 26 Item 4. Mine Safety Disclosures 27 Part II 28 Item 5. Market for Registrant's Common Equity; Related Stockholder Matters and Issuer Purchases of Equity Securities 28 Item 6. [Reserved] 30 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 30 Item 7A.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 36 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 36 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 36 Item 9A.

Controls and Procedures

Controls and Procedures 36 Item 9B. Other Information 37 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 37 Part III 38 Item 10. Directors, Executive Officers and Corporate Governance 38 Item 11.

Executive Compensation

Executive Compensation 41 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42 Item 13. Certain Relationships and Related Transactions, and Director Independence 43 Item 14. Principal Accountant Fees and Services 45 Part IV 46 Item 15. Exhibits and Financial Statement Schedules 46

Signatures

Signatures 47 Nutra Pharma Corp ("Nutra Pharma") and its wholly owned subsidiaries, ReceptoPharm, Inc. ("ReceptoPharm") and Designer Diagnostics Inc. are referred to herein as "we", "our" or "us" (ReceptoPharm is also individually referred to herein). Forward Looking Statements This Annual Report on Form 10-K for the period ending December 31, 2023 contains forward-looking statements that involve risks and uncertainties , most significantly, Item 7 (Management's Discussion and Analysis of Financial Condition and Results of Operation), as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The words or phrases "would be," "will allow, "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." All statements other than statements of historical fact, are statements that could be deemed forward-looking statements, including any projections of revenue, gross margin, expenses, earnings or losses from operations, synergies or other financial items; any statements of the plans, strategies and objectives of management for future operations; and any statement concerning developments, plans, or performance. Unless otherwise required by applicable law, we do not undertake and we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. 2 PART I Item 1. Business Introduction Nutra Pharma is a biopharmaceutical company with intellectual property for drugs that treat autoimmune disorders, viral diseases and pain. Nutra Pharma was incorporated under the laws of the state of California on February 1, 2000, under the original name of Exotic-Bird.com. Nutra Pharma conducts drug

View Full Filing

View this 10-K filing on SEC EDGAR